Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Gallamini A, et al. Among authors: patti c. J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 2007 Jul 23. J Clin Oncol. 2007. PMID: 17646666
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A. Zinzani PL, et al. Among authors: patti c. EClinicalMedicine. 2023 Aug 10;62:102131. doi: 10.1016/j.eclinm.2023.102131. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599908 Free PMC article.
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.
Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, Aversa S, Billio A, Porcellini A, Candela M, Centurioni R, Congiu AM, Brunori M, Nati S, Spriano M, Vimercati R, Marino G, Contu A, Tedeschi L, Majolino I, Crugnola M, Sertoli MR; NHLCSG. Olivieri A, et al. Among authors: patti c. Ann Oncol. 2005 Dec;16(12):1941-8. doi: 10.1093/annonc/mdi399. Epub 2005 Sep 12. Ann Oncol. 2005. PMID: 16157621 Free article. Clinical Trial.
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Ladetto M, et al. Among authors: patti c. Leukemia. 2006 Oct;20(10):1840-7. doi: 10.1038/sj.leu.2404346. Epub 2006 Aug 24. Leukemia. 2006. PMID: 16932351 Clinical Trial.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C. Gallamini A, et al. Among authors: patti c. Blood. 2007 Oct 1;110(7):2316-23. doi: 10.1182/blood-2007-02-074641. Epub 2007 Jun 20. Blood. 2007. PMID: 17581918 Free article. Clinical Trial.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Among authors: patti c. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: patti c. J Clin Oncol. 2008 Jul 1;26(19):3166-75. doi: 10.1200/JCO.2007.14.4204. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490650
Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study.
Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M, Hassan C, Cottone M, Zullo A. Andriani A, et al. Among authors: patti c. Dig Liver Dis. 2009 Jul;41(7):467-73. doi: 10.1016/j.dld.2008.09.009. Epub 2008 Oct 21. Dig Liver Dis. 2009. PMID: 18945654
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Gallamini A, et al. Among authors: patti c. Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x. Epub 2010 Dec 20. Br J Haematol. 2011. PMID: 21166786 Free article. Clinical Trial.
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: patti c. J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189387
147 results